We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Smart Nanoparticle Drug Delivery System Avoids Tumor-Protecting Obstacles

By LabMedica International staff writers
Posted on 13 Apr 2016
As a clearer image of the tumor microenvironment emerges, nanoparticle drug transport systems have evolved to overcome obstacles that prevent effective delivery of the chemotherapeutic agent.

A pertinent example is the triple-stage "cluster bomb" approach that has been developed by researchers at Emory University (Atlanta, GA, USA) and their colleagues at the University of Science and Technology of China (Hefei). 

The smart polymeric clustered nanoparticles (iClusters) developed by these investigators had an initial size of approximately 100 nanometers, which was favorable for long-term blood circulation and induced the particles to collect at tumor sites. More...
Once the iCluster particles accumulated at tumor sites, the intrinsic tumor extracellular acidity triggered the discharge of platinum prodrug-conjugated poly(amidoamine) dendrimers (diameter about five nanometers). Such a structural alteration promoted tumor penetration and cell internalization of the therapeutics. The internalized dendrimer prodrugs were further reduced intracellularly to release the drug cisplatin to kill the cancer cells.

The investigators reported in the March 28, 2016, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS) that they had validated the superior in vivo antitumor activities of the iCluster particles in several intractable mouse tumor models including poorly permeable pancreatic cancer, drug-resistant cancer, and metastatic cancer, which demonstrated their versatility and broad applicability.

"The negative side effects of cisplatin are a long-standing limitation for conventional chemotherapy," said contributing author Dr. Jinzhi Du, a postdoctoral researcher at Emory University. "In our study, the delivery system was able to improve tumor penetration to reach more cancer cells, as well as release the drugs specifically inside cancer cells through their size-transition property."

Related Links:

Emory University
University of Science and Technology of China



New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Automated Clinical Chemistry Analyzer
Envoy 500+
New
Steam Sterilizer
Hi Vac II Line
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.